ReviewCarbon Ion Radiotherapy in the Treatment of Pancreatic Cancer A ReviewMalouff, Timothy D. MD∗; Krishnan, Sunil MBBS, MD∗; Hallemeier, Christopher L. MD†; Haddock, Michael G. MD†; Hoppe, Bradford S. MD∗; Beltran, Chris PhD†; Mahajan, Anita MD†; Trifiletti, Daniel M. MD∗,†Author Information From the ∗Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL †Department of Radiation Oncology, Mayo Clinic, Rochester, MN. Received for publication December 10, 2019; accepted April 14, 2020. Address correspondence to: Daniel M. Trifiletti, MD, Mayo Clinic Florida, Department of Radiation Oncology, 4500 San Pablo Road S, Mayo 1N, Jacksonville, FL 32224 (e-mail: email@example.com). D.M.T. has received clinical trial funding from Novocure and publishing fees from Springer. The remaining authors declare that they have no conflict of interest. This article does not contain any studies with human participants or animals performed by any of the authors. Pancreas: July 2020 - Volume 49 - Issue 6 - p 737-743 doi: 10.1097/MPA.0000000000001566 Buy Metrics Abstract Pancreatic cancer is the fourth most common cause of cancer-related morality worldwide, and the prognosis remains poor despite aggressive therapy. Carbon ion radiotherapy has favorable radiobiological and physical characteristics in the treatment, including a higher linear energy transfer and higher relative biological effectiveness, which increase the cell kill while potentially reducing toxicities to nearby normal tissues. Although small, early clinical studies have shown promise in both the resectable and unresectable settings to improve local control and overall survival while minimizing toxicities. Currently, there are several trials, including 2 sponsored by institutions in the United States, investigating the role of carbon ion radiotherapy for the treatment of locally advanced pancreatic cancer. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.